文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

人类鼠疫耶尔森菌减毒活疫苗挑战模型的开发:2025年1月临床试验考虑专家咨询

Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025.
PubMed 文献 · Vaccine · 2025-07-12

鼠疫疫苗开发是大流行防范优先事项,但现场试验难以获得许可所需数据。2025年1月我们召开为期一天的专家咨询研讨会,评估开展鼠疫耶尔森菌人类疫苗挑战研究的可行性,讨论实践、监管及未来用途。研讨会识别多项挑战并讨论应对策略,为建立合作联盟开发挑战模型奠定基础。

要点

  • 鼠疫在非洲、南美和亚洲部分国家呈地方性流行,存在人兽共患溢出和流行传播风险。
  • 现场试验难以生成疫苗许可所需充分数据,人类感染对照研究已用于低散发疾病疫苗测试。
  • 2025年1月专家咨询会讨论鼠疫减毒活疫苗挑战模型的可行性、监管与伦理挑战。

核心结论

  • 研讨会识别了开展鼠疫耶尔森菌人类疫苗挑战模型的若干挑战并讨论了潜在应对策略。
  • 下一步包括早期公众参与、菌株表征和监管讨论,以界定研究数据如何用于评估疫苗效力。
  • 愿景是建立全球网络,推进针对这一古老疾病的新疫苗技术。

研究设计与样本

  • 2025年1月举办为期一天的专家咨询研讨会,邀请学术界、产业界、监管机构、资助方等鼠疫耶尔森菌生物学与感染专家参加。
  • 研讨会结合报告与分组讨论,分为五个环节:减毒活疫苗介绍、当代鼠疫疫苗格局更新、生物安全与生物安保考量、临床与伦理考量、公众认知。

主要发现

  • 鼠疫在非洲、南美和亚洲部分国家仍呈地方性流行,存在人兽共患溢出和流行传播或故意释放威胁。
  • 现场试验难以生成疫苗许可所需的充分数据。
  • 人类感染对照研究已用于暴发低散发且现场试验困难的疾病候选疫苗测试,通常使用减毒活疫苗或疫苗型菌株测量临床或微生物学终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Yersinia pestis is the causative agent of plague - the archetypal bacterial pandemic disease. Plague remains endemic in several countries in Africa, South America, and Asia, posing high risks of zoonotic spill-over and epidemic spread or threat of deliberate release. Plague vaccine development remains a priority for pandemic preparedness initiatives but generating sufficient field data for vaccine licensure is challenging. Controlled human infection studies have been deployed to test candidate vaccines against diseases with low and sporadic incidences of outbreaks where field trials are difficult. Typically, such studies use live attenuated or vaccine-type strains to measure clinical or microbiological end points of interest. To assess the feasibility of conducting a human vaccine-challenge study for Y. pestis, we hosted a one-day expert consultation workshop in January 2025. The aim was to discuss the practical, regulatory landscape and future use-case of such a model. We invited attendees from academia, industry, regulatory bodies, funders, and other stakeholders with expertise in Y. pestis biology and infection. The workshop combined presentations with breakout discussions and was divided into five sessions: i) Introduction to live attenuated Y. pestis vaccines; ii) Update of the contemporary plague vaccine landscape; iii) Assessment of biosafety and bio-security considerations; iv) Clinical and ethical considerations and v) public perceptions. Several challenges were identified, and potential strategies to address them were discussed. This perspective builds on this workshop and lays the foundation for a collaborative consortium to develop a Y. pestis vaccine challenge model. Next steps include early-stage public engagement, strain characterization, and regulatory discussions to define how data from these studies could be used for assessing vaccine efficacy. Our vision is to establish a global network dedicated to advancing new vaccine technologies for an ancient disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rydlova A, Smith E, Stuart A, et al. Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025. Vaccine. 2025. PMID: 40652682. doi:10.1016/j.vaccine.2025.127492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。